<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01923376</url>
  </required_header>
  <id_info>
    <org_study_id>401550</org_study_id>
    <nct_id>NCT01923376</nct_id>
  </id_info>
  <brief_title>Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)</brief_title>
  <acronym>HELP</acronym>
  <official_title>Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Methodist Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Methodist Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the use of polyethylene glycol is superior
      and more safe in treating hepatic encephalopathy compared to lactulose and also to determine
      if treatment with polyethylene glycol will reduce the duration of hospital stay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic encephalopathy is the occurrence altered level of consciousness as a result of
      cirrhosis and liver failure. Main treatment goal for hepatic encephalopathy is to eliminate
      the precipitating factor and to decrease circulating ammonia level. Current standard for
      treating HE is treatment with Lactulose. Lactulose are metabolized by colonic bacteria to
      byproducts which cause catharsis and reduces pH, thereby inhibiting ammonia absorption.
      However, there is limited evidence available to demonstrate the efficacy. Studies on animal
      model have suggested that polyethylene glycol 3350-electrolyte solution (GOLYTELY) is
      effective in clearing gut bacteria and reducing the ammoniagenesis in colon. Recently
      published study by Robert Rahimi, University of Texas Southwestern Medical Center found that
      polyethylene glycol is more effective in improving HE over the first 24 hours compared to
      lactulose and also may reduce duration of hospital stay.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Not enough staff to collect data
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of cognition</measure>
    <time_frame>24 hours from the time of enrollment</time_frame>
    <description>Subjects will be evaluated every 24hr from the time of enrollment to assess for improvement of cognition until back to baseline and/or grade 0 based on HESA scare</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>From time of admission to time of discharge an approximate length of seven days</time_frame>
    <description>To determine if treatment with polyethylene glycol compared to lactulose will reduce the duration of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <condition>HE</condition>
  <condition>Cirrhosis</condition>
  <condition>Altered Mental Status</condition>
  <condition>AMS</condition>
  <arm_group>
    <arm_group_label>Lactulose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>per standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>polyethylene glycol 3350 (Golytely)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>If randomized to this group, subjects will receive 10 - 30 grams of lactulose per standard of care</description>
    <arm_group_label>Lactulose</arm_group_label>
    <other_name>Enulose, Duphalac, generlac, kristalose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene Glycol 3350</intervention_name>
    <description>If subject is randomized to this group, one time dose of one gallon polyethylene glycol 3350 will be given at the time of enrollment</description>
    <arm_group_label>polyethylene glycol 3350 (Golytely)</arm_group_label>
    <other_name>Miralax</other_name>
    <other_name>Golytely</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 80

          -  Male and female of all races and ethnicities

          -  Cirrhosis of any cause

          -  Any grade of hepatic encephalopathy (1-4)

          -  Representatives have to be willing to comply with all protocol procedures and to
             understand, sign and date an informed consent document and authorize access to
             protected health information on the subject's behalf

        Exclusion Criteria:

          -  Acute liver failure

          -  Prisoners

          -  Structural brain lesions (as indicated by CT and confirmed by neurological exam)

          -  Other causes of altered mental status

          -  Previous use of rifaximin or neomycin within last 7 days

          -  Pregnancy

          -  Serum Na &lt;125 MEq/liter

          -  Receiving more than 1 dose (30 cc) of lactulose prior to enrollment

          -  Uncontrolled infection with hemodynamic instability requiring vasopressors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Smruti R Mohanty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Methodist Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2013</study_first_posted>
  <last_update_submitted>May 9, 2015</last_update_submitted>
  <last_update_submitted_qc>May 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Methodist Hospital</investigator_affiliation>
    <investigator_full_name>Smruti R Mohanty, MD</investigator_full_name>
    <investigator_title>Chief of Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>hepatic encephalopathy</keyword>
  <keyword>hepatic coma</keyword>
  <keyword>HE</keyword>
  <keyword>PSE</keyword>
  <keyword>lactulose</keyword>
  <keyword>golytely</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>Hepatic Insufficiency</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>Brain Damage, Chronic</keyword>
  <keyword>Delirium</keyword>
  <keyword>Encephalitis</keyword>
  <keyword>Neurotoxicity Syndromes</keyword>
  <keyword>Liver Failure</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Brain Diseases, Metabolic</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Confusion</keyword>
  <keyword>Neurobehavioral Manifestations</keyword>
  <keyword>Neurologic Manifestations</keyword>
  <keyword>Signs and Symptoms</keyword>
  <keyword>Delirium, Dementia, Amnestic, Cognitive Disorders</keyword>
  <keyword>Mental Disorders</keyword>
  <keyword>Central Nervous System Viral Diseases</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Central Nervous System Infections</keyword>
  <keyword>Poisoning</keyword>
  <keyword>Substance-Related Disorders</keyword>
  <keyword>Citric Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyethylene glycol 3350</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

